Dynavax Technologies (DVAX) 10.91 $DVAX INVESTOR ALERT:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dynavax Technologies (DVAX) 10.91 $DVAX

INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Dynavax Technologies Corporation and Advises Investors to Contact the Firm
BusinessWire - Fri Sep 02, 6:51PM CDT
Goldberg Law PC announces that it is investigating Dynavax Technologies Corporation ("Dynavax" or the "Company" (Nasdaq: DVAX) concerning possible violations of federal securities laws.
DVAX: 10.91 (-5.03)

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Dynavax Technologies Corporation - DVAX
BusinessWire - Fri Sep 02, 5:25PM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dynavax Technologies Corporation (NASDAQVAX) resulting from allegations that Dynavax may have issued materially misleading business information to the investing public.
DVAX: 10.91 (-5.03)

Dynavax Reports Second Quarter 2016 Financial Results
Marketwire Canada - Fri Aug 05, 4:52PM CDT
BERKELEY, CA--(Marketwired - August 05, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016.
DVAX: 10.91 (-5.03)

Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
Marketwire Canada - Fri Aug 05, 4:32PM CDT
Advisory Committee Meeting Scheduled for November 16, 2016
DVAX: 10.91 (-5.03)

The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
DVAX: 10.91 (-5.03), HRTX: 17.70 (-0.63), LJPC: 16.15 (-0.33), PETX: 8.81 (-0.11)

Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:33AM CDT
What's in store for drug stocks Dynavax, Aratana and others when they report their Q2 results on Aug 5?
DVAX: 10.91 (-5.03), JNJ: 119.32 (+0.24), HRTX: 17.70 (-0.63), GILD: 76.89 (-0.53), LJPC: 16.15 (-0.33), PETX: 8.81 (-0.11)

Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions
Marketwired - Sat Jun 11, 10:00AM CDT
Pivotal Phase 3 Data Show Investigational Two-Dose Hepatitis B Vaccine Provides a Significantly Higher Rate of Seroprotection Than an Approved Vaccine in Patients With Type 2 Diabetes
DVAX: 10.91 (-5.03)

Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 10.91 (-5.03), PACB: 8.28 (-0.02), AVXL: 3.05 (+0.02), PPHM: 0.38 (+0.02)

Dynavax to Present at Two Upcoming Investor Conferences
Marketwired - Wed May 18, 6:01AM CDT
BERKELEY, CA--(Marketwired - May 18, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows:
DVAX: 10.91 (-5.03)

Dynavax Technologies Down 16.5% Since SmarTrend Downtrend Call (DVAX)
Comtex SmarTrend(R) - Fri May 13, 1:38PM CDT
SmarTrend identified a Downtrend for Dynavax Technologies (NASDAQVAX) on April 27th, 2016 at $18.36. In approximately 2 weeks, Dynavax Technologies has returned 16.54% as of today's recent price of $15.32.
DVAX: 10.91 (-5.03)

Dynavax Technologies reports 1Q loss
Automated Insights - Mon May 09, 8:05AM CDT
BERKELEY, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Monday reported a loss of $27 million in its first quarter.
DVAX: 10.91 (-5.03)

Dynavax Reports First Quarter 2016 Financial Results
Marketwire Canada - Mon May 09, 8:02AM CDT
BERKELEY, CA--(Marketwired - May 09, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016.
DVAX: 10.91 (-5.03)

Does This Upstart Pose a Threat to GlaxoSmithKline?
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 7:40AM CDT
SOURCE: GLAXOSMITHKLINE PLC. GlaxoSmithKline plc generates more than $1.2 billion per quarter selling vaccines that are used to treat infectious disease, and one of GlaxoSmithKline's top-selling vaccines is Engerix-B, a vaccine used to prevent...
DVAX: 10.91 (-5.03), GSK: 44.26 (+1.28)

Downgrade Alert for Dynavax Technologies (DVAX)
Comtex SmarTrend(R) - Fri Apr 29, 4:01AM CDT
Dynavax Technologies (NASDAQVAX) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $17.53 on volume of 1.1 million shares, above average daily volume of 901,000. Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways.
DVAX: 10.91 (-5.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 49

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 84

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading

Top 5 Most Recently Viewed Articles

DatChat Receives Mexican Patent for Enhanced Privacy Solutions

Updated Category News Views 157

DatChat's Latest Patent Achievement New Brunswick, NJ - DatChat, Inc. (NASDAQ: DATS), a leading company in secure messaging and social media, has exciting news to share. Recently, the Mexican Patent office issued a Notice of Allowance for DatChat's patent application titled "Systems and Methods of Transforming Electronic Content." This development follows the company...

Continue Reading
Flora Growth Partners with Canopy to Enhance Cannabis Access

Updated Category News Views 111

Flora Growth Enters the Australian Medical Cannabis Market Flora Growth Corp (NASDAQ: FLGC) has recently taken a significant step into the Australian medical cannabis arena through its strategic partnership with Canopy Growth Corp (NASDAQ: CGC). A distribution agreement has been signed, allowing Flora's subsidiary, Australian Vaporizers, to handle the distribution of...

Continue Reading
Digital Brands Group Sets Public Offering of 11.36 Million Units

Updated Category News Views 167

Digital Brands Group Projects Strong Growth with New Offering Digital Brands Group, Inc. (OTC PINK: DBGI), a unique entity known for curating luxury lifestyle brands, has recently made headlines with their announcement regarding a public offering. This initiative, which involves an impressive volume of 11.36 million units, is set to make waves in the market. Details of...

Continue Reading
Unraveling Solana's Remarkable Rise From $11 to $166

Updated Category News Views 154

Unraveling Solana's Remarkable Rise From $11 to $166 Solana (SOL), a cryptocurrency that emerged in March 2020, has astonished investors with its dramatic increase in value. It has risen more than 15 times its initial value, predominantly bolstered by a vibrant ecosystem that has flourished around various meme coins. Jim Cramer’s Warning In 2022, Jim Cramer, a prominent...

Continue Reading
LO3 Capital Revolutionizes Travel Services with CCRA Deal

Updated Category News Views 189

LO3 Capital Makes Strategic Investment in CCRA International LO3 Capital, a dynamic private investment firm, is making waves with its recent senior debt investment in CCRA International, Inc. This relationship is pivotal for CCRA, a technology-driven travel services platform, as it progresses towards acquiring ABC Global Services. This acquisition is set to form one of...

Continue Reading